Welcome to our dedicated page for Appyea news (Ticker: APYP), a resource for investors and traders seeking the latest updates and insights on Appyea stock.
AppYea Inc. (APYP) reports developments around blockchain-enabled trust infrastructure for regulated outcome-driven markets, including lottery and gaming environments. The company’s updates center on the completed Techlott technology acquisition, the Techlott decentralized randomness and verification architecture, and the NEO Infrastructure Layer for audit-ready deployment in regulated markets.
Company announcements also address commercialization of licensing frameworks, integration of acquired technology, executive and board appointments, private placements, governance alignment, and capital-markets planning. AppYea’s technology focus includes smart contracts, verifiable randomness, and real-time result verification for transparent outcome processing.
Summary not available.
AppYea Inc. (OTCQB:APYP) announced the immediate addition of Adi Shemer to its advisory board. Shemer has a robust background in operations management within the medical device sector, having held senior executive positions, including CEO at TR bike Ltd. and Tzora Active Systems Ltd. He aims to enhance the production and distribution of AppYea's innovative wearable device, DreamIT, designed to improve sleep quality. The company's focus remains on commercialization, backed by a strong IP portfolio and positive market feedback. This strategic move comes as AppYea transitions from development to commercial operations, indicating growth potential in the sleep health market.
AppYea Inc. (OTCQB:APYP) has appointed Ron Mekler as an independent director and Chair of the Audit Committee, effective immediately. This strategic move aims to enhance the company's board and management using Mekler's extensive experience in finance and healthcare. Mekler previously served as CFO at Clalit Health Services, Israel's largest health organization, and has a robust background in various industries. He expressed confidence in AppYea's potential and its innovative sleep monitoring solutions, which are protected by multiple patents. This leadership change is expected to strengthen the firm's market position and attract partnerships.
SleepX, a subsidiary of AppYea (OTC:APYP), has launched its innovative product DreamIT, a wristband designed to treat sleep apnea and snoring through biofeedback. The initial version has completed testing, with production targeting 20,000 units monthly. Retail price starts at $149, with a holiday discount price of $99. DreamIT monitors vital signs like pulse and blood oxygen, while the accompanying app provides health analytics and alerts. The company is pursuing partnerships with major distributors and considering options with smartphone manufacturers.